多替拉韦加拉米夫定简化治疗1年后APOBEC3诱导的缺陷HIV DNA比例:ANRS 167 LAMIDOL试验
ANRS 167 LAMIDOL试验纳入104例病毒学抑制的HIV感染者,在换用多替拉韦加拉米夫定双药治疗前8周(W-8)和治疗48周后(W48)采集PBMC,用二代测序检测Vif和RT区APOBEC3诱导的缺陷前病毒及APOBEC3相关耐药突变。结果示缺陷前病毒患者比例无显著变化,但APOMuts富集增加。
要点
- W-8和W48时Vif区缺陷前病毒患者比例分别为22%和29%,RT区分别为38%和42%。
- 至少一个APOMut的患者比例从W-8的27%升至W48的38%。
- APOMuts与潜在APOMut位点比值W48为16.5%,显著高于W-8的9.8%(P=0.007)。
核心结论
- 多替拉韦加拉米夫定维持治疗1年后,APOBEC3缺陷前病毒患者比例无显著变化,但观察到APOMuts富集。
- 需要更长期的研究来评估双药治疗下其他形式的缺陷病毒。
研究设计与样本
- ANRS 167 LAMIDOL试验中,104例病毒学抑制患者从三药方案换用多替拉韦加拉米夫定双药治疗。
- 在双药治疗启动前8周(W-8)和启动后48周(W48)采集PBMC,对Vif和RT区进行二代测序。
- 开发生物信息学算法识别APOBEC3缺陷序列和APOBEC3相关耐药突变(APOMuts)。
- 所有超突变序列和含至少一个终止密码子的序列被视为缺陷。
主要发现
- 中位病毒学抑制持续时间4.2年(IQR:2.0-9.1)。
- W-8和W48时Vif区缺陷前病毒患者比例分别为22%和29%,RT区分别为38%和42%。
- 至少一个APOMut的患者比例在W-8为27%,W48为38%。
- APOMuts与潜在APOMut位点比值W48为16.5%,显著高于W-8的9.8%(P=0.007)。
- W-8时APOBEC3缺陷病毒的存在与HIV总DNA水平、换用多替拉韦加拉米夫定前第三类药物类别、病毒学抑制持续时间均无关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需要更长期的研究来评估双药治疗下其他形式的缺陷病毒。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hypermutated viruses induced by APOBEC3 (apolipoprotein B mRNA-editing, enzyme-catalytic, polypeptide-like 3) proteins comprise some of the defective viruses in the HIV reservoir. Here, we assessed the proportion of APOBEC3-induced defective proviruses in HIV-positive patients before and after receiving dolutegravir + lamivudine dual therapy. METHODS: PBMCs of virologically suppressed patients enrolled in the ANRS 167 LAMIDOL trial, evaluating a switch from triple therapy to dolutegravir + lamivudine, were collected 8 weeks before (W-8) and 48 weeks after (W48) dual-therapy initiation. The Vif and RT regions were subject to next-generation sequencing. Bioinformatic algorithms were developed to identify APOBEC3-defective sequences and APOBEC3-related drug resistance mutations (APOMuts). All hypermutated sequences and those containing at least one stop codon were considered as defective. RESULTS: One hundred and four patients were enrolled (median virological suppression duration: 4.2 years; IQR: 2.0-9.1). Proviral defective reads at W-8 and W48 were detected in Vif in 22% and 29% of patients, respectively, and in RT in 38% and 42% of patients, respectively. At least one APOMut was present in proviruses of 27% and 38% of patients at W-8 and W48, respectively. The ratio of APOMuts/number of potential APOMut sites was significantly higher at W48 (16.5%) than at W-8 (9.8%, P = 0.007). The presence of APOBEC3-defective viruses at W-8 was not associated with HIV total DNA level, nor with the third drug class received prior to switching to dolutegravir + lamivudine, nor with the duration of virological suppression. CONCLUSIONS: Whereas no significant change in the proportion of patients with APOBEC3-defective proviruses was evidenced after 1 year of dolutegravir + lamivudine maintenance, enrichment in APOMuts was observed. Further longer-term studies are needed to assess the other forms of defective viruses with dual-therapy.
引用
- Mazouz F, Bertine M, Coppée R, et al. Proportion of APOBEC3-induced defective HIV DNA after 1 year of dolutegravir + lamivudine simplification in the ANRS 167 LAMIDOL trial. J Antimicrob Chemother. 2023. PMID: 37930812. doi:10.1093/jac/dkad344
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。